-+ 0.00%
-+ 0.00%
-+ 0.00%

Dongsung Pharmaceutical Reports 25.87 Billion Won Derivatives Valuation Loss

PUBT·11/16/2026 15:11:03
Listen to the news
Dongsung Pharmaceutical Reports 25.87 Billion Won Derivatives Valuation Loss
  • Dongsung Pharmaceutical disclosed a KRW 25.87 billion derivatives valuation loss on Nov. 16, 2026.
  • The January-September loss represented 26.85% of equity of KRW 96.37 billion.
  • Rising share prices drove fair-value changes in conversion rights associated with convertible bonds.
  • The accounting loss involved no cash outflow.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dongsung Pharmaceutical Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261116802456), on November 16, 2026, and is solely responsible for the information contained therein.